MX2017002791A - Vacuna contra filovirus de virus vaccinia ankara modificado (mva) recombinante. - Google Patents
Vacuna contra filovirus de virus vaccinia ankara modificado (mva) recombinante.Info
- Publication number
- MX2017002791A MX2017002791A MX2017002791A MX2017002791A MX2017002791A MX 2017002791 A MX2017002791 A MX 2017002791A MX 2017002791 A MX2017002791 A MX 2017002791A MX 2017002791 A MX2017002791 A MX 2017002791A MX 2017002791 A MX2017002791 A MX 2017002791A
- Authority
- MX
- Mexico
- Prior art keywords
- mva
- recombinant
- relates
- vaccinia virus
- modified vaccinia
- Prior art date
Links
- 241001183012 Modified Vaccinia Ankara virus Species 0.000 title abstract 6
- 229960005486 vaccine Drugs 0.000 title abstract 3
- 241000711950 Filoviridae Species 0.000 title abstract 2
- 241001115402 Ebolavirus Species 0.000 abstract 2
- 102000003886 Glycoproteins Human genes 0.000 abstract 2
- 108090000288 Glycoproteins Proteins 0.000 abstract 2
- 241001115401 Marburgvirus Species 0.000 abstract 2
- 101710094648 Coat protein Proteins 0.000 abstract 1
- 208000007136 Filoviridae Infections Diseases 0.000 abstract 1
- 230000000890 antigenic effect Effects 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 239000002773 nucleotide Substances 0.000 abstract 1
- 125000003729 nucleotide group Chemical group 0.000 abstract 1
- 230000001681 protective effect Effects 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24041—Use of virus, viral particle or viral elements as a vector
- C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/14011—Filoviridae
- C12N2760/14111—Ebolavirus, e.g. Zaire ebolavirus
- C12N2760/14134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/14011—Filoviridae
- C12N2760/14211—Marburgvirus, e.g. lake Victoria marburgvirus
- C12N2760/14234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente invención se relaciona con una vacuna de filovirus mejorada que comprende una vacuna a base del virus vaccinia Ankara (a base de MVA) modificado recombinante contra la infección del filovirus y con productos, métodos y usos relacionados. Específicamente, la presente invención se relaciona con los vectores de MVA y FPV (recombinante) modificados genéticamente que comprenden al menos una secuencia de nucleótidos heteróloga que codifica un determinante antigénico de una glicoproteína del virus de Marburgo (MARV) o virus del Ébola. Específicamente, la invención se relaciona con un MVA recombinante que comprende una glicoproteína del virus del Ébola y una proteína virión 40. La invención también se relaciona con productos, métodos y usos de estos, así como también regímenes de sensibilización/refuerzo de MVA y FPV diseñados genéticamente (recombinantes), por ejemplo, adecuados para inducir una respuesta inmunitaria protectora en un sujeto.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462045538P | 2014-09-03 | 2014-09-03 | |
| US201462055154P | 2014-09-25 | 2014-09-25 | |
| PCT/EP2015/070161 WO2016034678A2 (en) | 2014-09-03 | 2015-09-03 | Recombinant modified vaccinia virus ankara (mva) filovirus vaccine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2017002791A true MX2017002791A (es) | 2017-05-30 |
Family
ID=54145734
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017002791A MX2017002791A (es) | 2014-09-03 | 2015-09-03 | Vacuna contra filovirus de virus vaccinia ankara modificado (mva) recombinante. |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US10576141B2 (es) |
| EP (1) | EP3188752A2 (es) |
| JP (2) | JP6823586B2 (es) |
| KR (2) | KR102736868B1 (es) |
| CN (2) | CN106999565B (es) |
| AU (2) | AU2015310909B2 (es) |
| CA (1) | CA2959105C (es) |
| IL (2) | IL250552B (es) |
| MX (1) | MX2017002791A (es) |
| MY (1) | MY193417A (es) |
| SG (2) | SG11201701506PA (es) |
| UA (1) | UA126848C2 (es) |
| WO (1) | WO2016034678A2 (es) |
| ZA (1) | ZA201701077B (es) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10130697B2 (en) | 2010-03-23 | 2018-11-20 | Wisconsin Alumni Research Foundation (Warf) | Vaccines comprising mutant attenuated influenza viruses |
| EP2747778B1 (en) | 2011-08-26 | 2017-12-06 | Wisconsin Alumni Research Foundation | Influenza viruses with mutant pb2 gene segment as live attenuated vaccines |
| US10053671B2 (en) | 2014-06-20 | 2018-08-21 | Wisconsin Alumni Research Foundation (Warf) | Mutations that confer genetic stability to additional genes in influenza viruses |
| DK3215187T3 (en) | 2014-11-04 | 2018-12-10 | Janssen Vaccines & Prevention Bv | THERAPEUTIC HPV16 VACCINES |
| CN111743601A (zh) * | 2014-11-26 | 2020-10-09 | 尼尔拉维有限公司 | 从血管除去阻塞性血栓的取血栓装置 |
| WO2016115116A1 (en) | 2015-01-12 | 2016-07-21 | Geovax, Inc. | Compositions and methods for generating an immune response to a hemorrhagic fever virus |
| JP2018510143A (ja) * | 2015-02-25 | 2018-04-12 | メモリアル スローン ケタリング キャンサー センター | 不活化非複製改変ワクシニアウイルスアンカラ（ｍｖａ）の固形腫瘍のための単独療法又は免疫チェックポイント遮断剤併用における使用 |
| WO2016168771A2 (en) | 2015-04-17 | 2016-10-20 | Alpine Immune Sciences, Inc. | Immunomodulatory proteins with tunable affinities |
| PL3402802T3 (pl) | 2016-01-08 | 2023-06-05 | Geovax, Inc. | Kompozycje i sposoby generowania odpowiedzi immunologicznej względem antygenu powiązanego z guzem nowotworowym |
| US20190030157A1 (en) | 2016-02-03 | 2019-01-31 | Geovax Inc. | Compositions and Methods for Generating an Immune Response to a Flavivirus |
| EP3417056A1 (en) | 2016-02-19 | 2018-12-26 | Wisconsin Alumni Research Foundation (WARF) | Improved influenza b virus replication for vaccine development |
| AU2017250358B2 (en) | 2016-04-15 | 2023-06-01 | Alpine Immune Sciences, Inc. | ICOS ligand variant immunomodulatory proteins and uses thereof |
| MA43552A (fr) | 2016-04-15 | 2018-11-07 | Alpine Immune Sciences Inc | Protéines immunomodulatrices à variants de cd80 et leurs utilisations |
| BR112018072372A2 (pt) * | 2016-05-02 | 2019-02-19 | Janssen Vaccines & Prevention B.V. | combinações de vacina terapêutica contra o hpv |
| EP3484507A1 (en) | 2016-07-15 | 2019-05-22 | Janssen Vaccines & Prevention B.V. | Methods and compositions for inducing protective immunity against a marburg virus infection |
| US11834490B2 (en) | 2016-07-28 | 2023-12-05 | Alpine Immune Sciences, Inc. | CD112 variant immunomodulatory proteins and uses thereof |
| AU2017345764A1 (en) * | 2016-10-20 | 2019-05-02 | Alpine Immune Sciences, Inc. | Secretable variant immunomodulatory proteins and engineered cell therapy |
| AU2018235835A1 (en) | 2017-03-16 | 2019-09-05 | Alpine Immune Sciences, Inc. | PD-L2 variant immunomodulatory proteins and uses thereof |
| KR20250083578A (ko) | 2017-03-16 | 2025-06-10 | 알파인 이뮨 사이언시즈, 인코포레이티드 | Cd80 변이체 면역조절 단백질 및 그의 용도 |
| US11173204B2 (en) | 2017-04-06 | 2021-11-16 | Janssen Vaccines & Prevention B.V. | MVA-BN and Ad26.ZEBOV or Ad26.filo prime-boost regimen |
| KR20200003921A (ko) | 2017-05-15 | 2020-01-10 | 얀센 백신스 앤드 프리벤션 비.브이. | 안정한 바이러스-함유 조성물 |
| KR102658198B1 (ko) | 2017-05-15 | 2024-04-16 | 얀센 백신스 앤드 프리벤션 비.브이. | 안정한 바이러스 함유 조성물 |
| WO2019018501A1 (en) * | 2017-07-18 | 2019-01-24 | Geovax Inc. | COMPOSITIONS AND METHODS FOR GENERATING LASV IMMUNE RESPONSE |
| US11311612B2 (en) | 2017-09-19 | 2022-04-26 | Geovax, Inc. | Compositions and methods for generating an immune response to treat or prevent malaria |
| GB201716181D0 (en) * | 2017-10-04 | 2017-11-15 | Univ Cape Town | Recombinant mva with modified hiv-1 env |
| EP4442268A3 (en) | 2017-10-10 | 2025-04-02 | Alpine Immune Sciences, Inc. | Ctla-4 variant immunomodulatory proteins and uses thereof |
| AU2018351000B2 (en) | 2017-10-18 | 2023-11-30 | Alpine Immune Sciences, Inc. | Variant ICOS Ligand immunomodulatory proteins and related compositions and methods |
| EP3700562A1 (en) | 2017-10-25 | 2020-09-02 | Wisconsin Alumni Research Foundation (WARF) | Recombinant influenza viruses with stabilized ha for replication in eggs |
| EP3735417A1 (en) | 2018-01-03 | 2020-11-11 | Alpine Immune Sciences, Inc. | Multi-domain immunomodulatory proteins and methods of use thereof |
| JP7783047B2 (ja) * | 2018-08-07 | 2025-12-09 | ウィスコンシン アルムニ リサーチ ファンデイション | 組換えの生物学的に封じ込められたフィロウイルスワクチン |
| US11389523B2 (en) | 2018-08-20 | 2022-07-19 | Wisconsin Alumni Research Foundation (Warf) | Vectors for eliciting immune responses to non-dominant epitopes in the hemagglutinin (HA) protein |
| US12150988B2 (en) | 2018-09-06 | 2024-11-26 | Bavarian Nordic A/S | Storage improved poxvirus compositions |
| US20220040284A1 (en) * | 2018-09-28 | 2022-02-10 | The Chancellor, Masters And Scholars Of The University Cambridge | Vaccines and methods |
| WO2020163804A1 (en) | 2019-02-08 | 2020-08-13 | Wisconsin Alumni Research Foundation (Warf) | Humanized cell line |
| WO2020223699A1 (en) | 2019-05-01 | 2020-11-05 | Wisconsin Alumni Research Foundation (Warf) | Improved influenza virus replication for vaccine development |
| US11807872B2 (en) | 2019-08-27 | 2023-11-07 | Wisconsin Alumni Research Foundation (Warf) | Recombinant influenza viruses with stabilized HA for replication in eggs |
| WO2021150874A1 (en) | 2020-01-24 | 2021-07-29 | Wisconsin Alumni Research Foundation (Warf) | Recombinant influenza viruses with stabilized na |
| US20230114464A1 (en) | 2020-03-12 | 2023-04-13 | Bavarian Nordic A/S | Conditions Improving Poxvirus Stability |
| US12290562B2 (en) | 2020-03-25 | 2025-05-06 | Wisconsin Alumni Research Foundation (Warf) | Recombinant multivalent influenza viruses |
| CN115819616B (zh) * | 2021-07-28 | 2025-04-11 | 江苏瑞科生物技术股份有限公司 | 一种基因重组vzv融合蛋白及其制备方法和应用 |
| WO2024188801A1 (en) | 2023-03-10 | 2024-09-19 | Bavarian Nordic A/S | Use of quail cell lines for poxvirus production |
| WO2024188803A1 (en) | 2023-03-10 | 2024-09-19 | Bavarian Nordic A/S | Production of poxviruses from quail cell cultures |
| WO2024188802A1 (en) | 2023-03-10 | 2024-09-19 | Bavarian Nordic A/S | Methods of isolating poxviruses from avian cell cultures |
| CN120843742A (zh) * | 2025-09-09 | 2025-10-28 | 军事科学院军事医学研究院军事兽医研究所 | 一种泛哺乳动物丝状病毒检测用引物组及其检测试剂盒和应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2776522C (en) * | 2001-10-01 | 2015-02-17 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Development of a preventive vaccine for filovirus infection in primates |
| EP1586331B1 (en) * | 2001-10-01 | 2008-05-28 | The Government of the U.S.A., as repr. by the Secretary, Dept. of Health & Human Services, the Nat. Inst. of Health | Development of a preventive vaccine for filovirus infection in primates |
| US20060088909A1 (en) * | 2002-05-17 | 2006-04-27 | Compans Richard W | Virus-like particles, methods of preparation, and immunogenic compositions |
| CA2581840C (en) * | 2004-09-27 | 2014-08-05 | Crucell Holland B.V. | Optimized vaccines to provide protection against ebola and other viruses |
| GB0706912D0 (en) * | 2007-04-10 | 2007-05-16 | Isis Innovation | Novel viral vaccines |
| EP2350270B1 (en) * | 2008-10-24 | 2018-03-07 | The Government of the United States of America, as represented by the Secretary, Department of Health & Human Services | Human ebola virus species and compositions and methods thereof |
| ES2618103T3 (es) | 2008-11-21 | 2017-06-20 | Bavarian Nordic A/S | Vector que comprende múltiples secuencias de nucleótidos homólogas |
| EP2473525A4 (en) * | 2009-09-02 | 2013-08-21 | Us Army | MONOCLONAL ANTIBODIES AGAINST GLYCOPROTEIN OF EBOLA SUDAN BONIFACE VIRUS |
| TR201902214T4 (tr) | 2010-04-16 | 2019-03-21 | Glaxosmithkline Biologicals Sa | Şempanze adenoviral vektörü-bazlı filovirüs aşıları. |
| AU2013245729B2 (en) | 2012-04-12 | 2016-09-29 | The Trustees Of The University Of Pennsylvania | Filovirus consensus antigens, nucleic acid constructs and vaccines made therefrom, and methods of using same |
| EP3639851A1 (en) * | 2012-09-04 | 2020-04-22 | Bavarian Nordic A/S | Methods and compositions for enhancing vaccine immune responses |
| GB201303406D0 (en) | 2013-02-26 | 2013-04-10 | Health Prot Agency | Crimean-Congo Haemorrhagic Fever Virus Antigenic Composition |
-
2015
- 2015-09-03 CN CN201580047328.1A patent/CN106999565B/zh active Active
- 2015-09-03 US US15/508,851 patent/US10576141B2/en active Active
- 2015-09-03 SG SG11201701506PA patent/SG11201701506PA/en unknown
- 2015-09-03 MY MYPI2017700483A patent/MY193417A/en unknown
- 2015-09-03 WO PCT/EP2015/070161 patent/WO2016034678A2/en not_active Ceased
- 2015-09-03 AU AU2015310909A patent/AU2015310909B2/en active Active
- 2015-09-03 MX MX2017002791A patent/MX2017002791A/es unknown
- 2015-09-03 KR KR1020177006091A patent/KR102736868B1/ko active Active
- 2015-09-03 CN CN202110238900.XA patent/CN112972668A/zh active Pending
- 2015-09-03 KR KR1020237030452A patent/KR102812180B1/ko active Active
- 2015-09-03 UA UAA201702987A patent/UA126848C2/uk unknown
- 2015-09-03 JP JP2017510880A patent/JP6823586B2/ja active Active
- 2015-09-03 SG SG10201901735XA patent/SG10201901735XA/en unknown
- 2015-09-03 EP EP15763853.7A patent/EP3188752A2/en active Pending
- 2015-09-03 CA CA2959105A patent/CA2959105C/en active Active
-
2017
- 2017-02-12 IL IL250552A patent/IL250552B/en unknown
- 2017-02-13 ZA ZA2017/01077A patent/ZA201701077B/en unknown
-
2020
- 2020-02-27 US US16/802,805 patent/US11338030B2/en active Active
-
2021
- 2021-01-06 JP JP2021000975A patent/JP7113924B2/ja active Active
- 2021-07-28 AU AU2021209228A patent/AU2021209228A1/en not_active Abandoned
-
2022
- 2022-01-23 IL IL290052A patent/IL290052A/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2017002791A (es) | Vacuna contra filovirus de virus vaccinia ankara modificado (mva) recombinante. | |
| ZA201707985B (en) | Recombinant modified vaccinia virus ankara (mva) foot and mouth disease virus (fmdv) vaccine | |
| MX361893B (es) | Vectores recombinantes de herpesvirus 3 galido (mdv serotipo 2) que expresan antigenos de patogenos de aves y sus usos. | |
| MX2021006931A (es) | Antigenos del virus de la inmunodeficiencia humana, vectores, composiciones y metodos de uso de estos. | |
| MX2020013153A (es) | Metodos y composiciones para inducir inmunidad protectora contra la infeccion por virus de inmunodeficiencia humana. | |
| MX2022010588A (es) | Vacuna basada en poxvirus recombinantes contra el virus sars-cov-2. | |
| MY173638A (en) | Parainfluenza virus 5 based vaccines | |
| PH12019500854A1 (en) | Recombinant vectors expressing antigens of avian influenza virus and uses thereof | |
| WO2012170765A3 (en) | Cmv glycoproteins and recombinant vectors | |
| EA202091516A1 (ru) | Способы и композиции для индукции иммунного ответа против вируса гепатита b (hbv) | |
| WO2017066706A8 (en) | Recombinant listeria vaccine strains and methods of using the same in cancer immunotherapy | |
| MX2016009072A (es) | Fusion de antigenos micobacterianos heterooligomericos. | |
| MX2023003746A (es) | Vacuna del virus vaccinia ankara modificado (mva) recombinante para virus sincicial respiratorio (vsr). | |
| WO2016116905A9 (en) | Cmv antigens and uses thereof | |
| MX2020006471A (es) | Metodos y composiciones para inducir una respuesta inmune contra el virus de hepatitis b (hbv). | |
| MX390966B (es) | Vacunas contra el dengue | |
| PH12019500578A1 (en) | New promoters | |
| PH12012502301A1 (en) | Parapoxvirus vectors containing rabies virus antigen | |
| MX2017012389A (es) | Vacuna del virus de la parotiditis recombinante jeryl lynn2. | |
| PH12018502430A1 (en) | Vaccines | |
| PH12013500122A1 (en) | Parapoxvirus vectors | |
| EA202193150A2 (ru) | Филовирусная вакцина на основе рекомбинантного модифицированного вируса осповакцины анкара (mva) | |
| WO2008118936A3 (en) | Method of elicting immune response with a modified mva viral hiv-1 vector | |
| PH12018500372A1 (en) | Fcv recombinant vaccines and uses thereof | |
| EP3939991A4 (en) | NOVEL RECOMBINANT INFLUENZA VIRUS EDUCATING IMMUNE AND THERAPEUTIC RESPONSES AGAINST HETEROLOGOUS INFLUENZA VIRUS, AND GENETIC VACCINE AND THERAPEUTIC VACCINE COMPRISING THEM |